Revelation Biosciences (NASDAQ:REVB) Trading Up 4.8% – What’s Next?

Shares of Revelation Biosciences, Inc. (NASDAQ:REVB) shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as $1.11 and last traded at $1.09. Approximately 106,923 shares traded hands during trading, an increase of 155% from the average daily volume of 41,852 shares. The stock had previously closed at $1.04.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Revelation Biosciences has an average rating of “Sell”.

Revelation Biosciences Trading Up 4.8%

The company has a market capitalization of $4.26 million, a PE ratio of -0.03 and a beta of -0.12. The business’s fifty day moving average is $1.03 and its two-hundred day moving average is $1.55.

Revelation Biosciences (NASDAQ:REVB) last issued its earnings results on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56). As a group, equities research analysts anticipate that Revelation Biosciences, Inc. will post -4.99 EPS for the current year.

Institutional Investors Weigh In On Revelation Biosciences

Several large investors have recently bought and sold shares of REVB. Geode Capital Management LLC purchased a new position in Revelation Biosciences in the 4th quarter worth about $27,000. Armistice Capital LLC purchased a new stake in shares of Revelation Biosciences during the 3rd quarter valued at about $114,000. Finally, Sabby Management LLC boosted its holdings in shares of Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after acquiring an additional 398,651 shares during the last quarter. 12.80% of the stock is currently owned by institutional investors.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.